

Q1 2025 *Results*



- We're off to a great start in 2025. Our investment in innovation and focus on pipeline value is paying off, as we see launches of new medicines and vaccines strongly contributing to our sales growth. •

Paul Hudson

Chief Executive Officer, Sanofi

Q1 2025 Company Sales

€9.9bn

+9.7% at constant exchange rates
+10.8% on a reported basis

Q1 2025 Business Earnings Per Share

€1.79

+15.7% at constant exchange rates
+17% on a reported basis

Sales by Category



Dupixent

€3.5bn



Pharma launches

€0.8bn



Vaccines

€1.3bn



Other medicines

€4.2bn

sanofi

Q1 2025 *Results*

Sales by Geography

US
€4.7bn

Europe
€2.0bn

Rest of the World
€3.2bn

Strong Pipeline Progress



- **6** regulatory approvals across medicines in immunology, rare diseases, and oncology.
- **5** regulatory submission acceptances for medicines in immunology and neurology.

Sustainability Strategy



Launch of AIR:

a refreshed approach on access to healthcare, environmental impact and the resilience of healthcare systems.

For further information on Q1 2025 results and definitions of financial indicators, please refer to the press release issued on April 24, 2025 at: www.sanofi.com/en/investors